3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
3
NIH
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
200
Neoplasms
116
Breast Neoplasms
112
Colorectal Neoplasms
97
Ovarian Neoplasms
78
Prostatic Neoplasms
75
Neoplasm Metastasis
74
Lung Neoplasms
66
Multiple Myeloma
64
Squamous Cell Carcinoma of Head and Neck
49
Pancreatic Neoplasms
48
Endometrial Neoplasms
48
Recurrence
46
Stomach Neoplasms
39
Carcinoma, Renal Cell
39
Small Cell Lung Carcinoma
38
Melanoma
38
Leukemia, Lymphocytic, Chronic, B-Cell
38
Leukemia, Myeloid, Acute
34
Lymphoma, Non-Hodgkin
30
Urinary Bladder Neoplasms
29
Parkinson Disease 4, Autosomal Dominant Lewy Body
29
Triple Negative Breast Neoplasms
28
Head and Neck Neoplasms
26
Carcinoma, Hepatocellular
26
Lymphoma, Large B-Cell, Diffuse
25
Lymphoma, Follicular
25
Esophageal Neoplasms
24
Advanced Solid Tumors
24
Lymphoma
23
Interventions
belzutifan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenoma, Islet Cell
×
30 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA